The Growth Hormone Peptide That Works With Your Feedback Loops, Not Around Them

There are two fundamentally different ways to raise growth hormone activity in the body. One is to inject synthetic GH directly, flooding receptors and bypassing the negative feedback loops that normally regulate release. The other is to signal the pituitary upstream and let it decide how much to release, on its own schedule. Tesamorelin belongs to the second category.

It's a 44-amino-acid synthetic analog of growth hormone releasing hormone (GHRH) — the same upstream signal your hypothalamus sends the pituitary under normal physiology. Tesamorelin binds the GHRH receptor on the anterior pituitary and triggers endogenous GH release in pulses, rather than delivering GH itself. The hormone produced is identical to what your body already makes; what differs is the route used to get there.

The FDA approved Tesamorelin (marketed as Egrifta) in 2010, specifically for HIV-associated lipodystrophy. In the registration trials that supported approval, patients showed roughly an 18% reduction in visceral adipose tissue — the metabolically active fat that sits deep around the abdominal organs and carries disproportionate cardiometabolic risk, as distinct from the subcutaneous fat under the skin, which tends to be harder to shift and wasn't the primary effect observed.

The mechanistic distinction from exogenous GH matters beyond semantics. Because Tesamorelin works through the natural GHRH-receptor pathway, it preserves the pulsatile release pattern — bursts followed by quiet periods — that the body's negative feedback loops are built around. Direct GH injection skips that regulation entirely, which is part of why receptor desensitization and downstream hormonal disruption are bigger concerns with exogenous GH than with GHRH-analog approaches.

It's worth being clear about scope: Tesamorelin's approval is for a specific medical population (HIV-associated lipodystrophy), and much of the discussion of broader use — general visceral fat reduction, metabolic effects outside that population — extends beyond what the approval trials directly established. The core mechanism is well characterized; the range of populations where the visceral-fat effect reliably generalizes is still being mapped out.

Why this matters for tracking: visceral fat doesn't show up reliably on a scale or in a mirror — it's a specific, metabolically consequential compartment that's best assessed through imaging or waist-to-hip ratio trends alongside relevant metabolic bloodwork (lipids, insulin sensitivity markers). If visceral adiposity is something you're actively managing, tracking those specific markers over time tells you far more than body weight alone.